REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:19 am EST
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 0.00015 million compared to KRW 0.00016 million a year ago. Net loss was KRW 100.92 million compared to net income of KRW 2,087.92 million a year ago. Basic loss per share from continuing operations was KRW 12 compared to basic earnings per share from continuing operations of KRW 116 a year ago. Basic loss per share was KRW 6 compared to basic earnings per share of KRW 116 a year ago.
For the nine months, sales was KRW 0.00083 million compared to negative sales of KRW 0.00016 million a year ago. Net income was KRW 4,572.73 million compared to KRW 3,569.03 million a year ago. Basic earnings per share from continuing operations was KRW 249 compared to KRW 196 a year ago. Basic earnings per share was KRW 249 compared to KRW 196 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
